Janssen Pharmaceutica NV v Juno Pharmaceuticals Pty Ltd

This case arose from a planned generic launch in the Australian pharmaceutical market. Janssen owned a patent concerning a dosing regimen associated with long-acting injectable paliperidone esters. Through Janssen-Cilag, it supplied the INVEGA range of paliperidone palmitate long-acting injectable products used in the treatment of schizophrenia. The judgment records that these products were the only paliperidone palmitate long-acting injectables then available on the Australian market.

Juno was a generic medicines supplier to retail pharmacies and hospitals. It had become the ARTG sponsor for two one-monthly paliperidone palmitate products, PALJUNA MONTHLY and VALINO MONTHLY, in multiple dose strengths. According to the judgment, Juno intended, unless restrained, to secure PBS listings and then supply those products into the market. Janssen said that if Juno took those steps, it would infringe three asserted claims of Janssen’s patent.

So the immediate dispute was not yet a final trial about who ultimately wins on patent infringement or validity. It was an urgent application asking the Federal Court to stop Juno from taking the final commercial steps needed to launch before the full case could be heard. That is often where the real commercial pressure sits in pharmaceutical patent litigation, because launch timing can have immediate market consequences.

The first applicant, Janssen Pharmaceutica NV, was the patent owner. The second applicant, Janssen-Cilag Pty Ltd, was the Australian sponsor on the ARTG for the INVEGA products and was licensed in respect of those goods. The respondent, Juno Pharmaceuticals Pty Ltd, was part of the DBG Group and supplied generic medicines to pharmacies and hospitals.

The conduct that triggered the dispute was Juno’s planned PBS listing and launch of its one-monthly paliperidone palmitate products. The judgment states that, unless restrained, Juno intended to secure PBS listings and then supply the products to retail pharmacies and hospitals. It also records Janssen’s allegation that Juno would, unless restrained, make or import the products, sell, use or otherwise exploit them, provide an assurance of supply for PBS listing purposes, and authorise others in the doing of those acts.

That matters because the case was not framed only around direct sale of a product. The catchwords and introductory passages show that the Court was also dealing with issues of authorisation or participation as a joint tortfeasor, and with infringing and non-infringing uses. In practical terms, the dispute was about the whole launch pathway, not just what happened after the first sale.

The Court applied the standard interlocutory injunction framework. First, Janssen had to show a prima facie case. The judgment quotes recent authority explaining that this does not require proof that success at trial is more probable than not. Instead, the applicant must show a sufficient likelihood of success to justify preserving the status quo in the circumstances.

In patent cases, that question becomes more complicated when the respondent says the patent is invalid. The judgment expressly notes that a sufficiently strong invalidity case may qualify whether there is a prima facie case of infringement at all. Here, Juno said it had a strong prima facie case that the asserted claims were invalid for want of inventive step and because of false suggestion made to the Commissioner of Patents.

Second, the Court had to consider the balance of convenience. That required comparing the likely prejudice and hardship to each side, and potentially to third parties and the public, depending on whether the injunction was granted or refused. A central issue in that exercise was whether damages later would adequately compensate the party who lost out in the meantime.

The structure of the reasons shows that the Court considered infringement, validity, the Pharmaceutical Benefits Scheme, likely price reductions, projected losses, other harm to Janssen, first mover advantage for Juno, and the comparative difficulty of calculating damages under different scenarios.

The judgment headings show that the Court examined product information documents for the relevant medicines, including the INVEGA SUSTENNA PI, the VALINO MONTHLY PI and the PALJUNA MONTHLY PI. That is a reminder that in pharmaceutical patent disputes, product information, indications, dosing instructions and launch materials can be central to infringement analysis, especially where method of treatment, regimen or Swiss-style claims are in issue.

The catchwords also show that the asserted patent issues were not limited to one legal pathway. They included a regimen claim, a method of treatment claim and a Swiss claim, as well as questions of authorisation or participation as a joint tortfeasor and the existence of infringing and non-infringing uses. Even from the limited public text available, it is clear that the Court was looking at how the products were intended to be used and supplied in practice, not just at abstract patent language.

For business readers, that is an important point. Courts often assess launch conduct by looking at the full commercial package, including regulatory documents, supply steps, intended market use and what the supplier is encouraging or enabling others to do. A business can face risk not only from direct acts, but also from conduct said to authorise or participate in infringement by others.

This was not just a technical patent argument. The judgment structure makes clear that the commercial mechanics of PBS entry were central. There is a dedicated section on the Pharmaceutical Benefits Scheme, followed by sections on price reductions for INVEGA products in a non-restraint scenario, whether additional generics would enter the market, projected losses arising from launch of the Juno products, and first mover advantage for Juno.

That matters because in a regulated market, launch can trigger consequences that are difficult to reverse. Once a generic product enters, pricing settings may change, reimbursement outcomes may shift, and the incumbent may suffer losses that are not easy to isolate or value later. The Court also specifically considered whether calculating damages on the usual undertaking in a restraint scenario would be more challenging than calculating damages in a non-restraint scenario.

In other words, the Court was not looking only at whether one side might lose some sales. It was considering the broader chain reaction that launch could cause. That is often decisive in urgent IP disputes. If the market changes in ways that are hard to unwind, preserving the status quo until trial can become the more practical course, even where validity is still contested.

Burley J granted the interlocutory application. The judgment’s summary of conclusions states: “For the reasons that follow, I am satisfied that the grant of the interlocutory relief sought is appropriate.” The catchwords also record that the application was granted.

The published headings indicate that the Court found there was a strong prima facie case that the Juno products would infringe. They also indicate that there was a prima facie case that the asserted claims may be invalid, with separate sections dealing with lack of inventive step and false suggestion. Even with that validity challenge in play, the Court ultimately concluded that interlocutory relief should be granted.

The orders published with the reasons do not set out the final operative restraint in full. Instead, they required the parties to confer and provide draft short minutes of order giving effect to the reasons, and to identify confidential parts of the reasons. The orders also restricted disclosure or publication of the reasons until further order, subject to specified exceptions. Because of that, the exact final terms of the injunction should be checked against the final published judgment and orders.

The key point for readers is that Juno was restrained on an interim basis pending further steps in the proceeding. But this was still not a final determination of patent validity or infringement.

Most businesses will never deal with schizophrenia medicines or PBS listing mechanics, but the decision still has broader value. It shows that courts do not assess urgent IP disputes in a vacuum. They look at the practical market consequences of allowing a launch to proceed before trial, and they may intervene where those consequences are difficult to reverse or compensate later.

If your business is planning to launch a product in a market where another party has patents or other registered rights, timing matters. A launch can be restrained even before the court finally decides the underlying dispute. That means legal risk should be assessed well before stock arrives, launch dates are announced, or supply commitments are made.

This case also shows the importance of documents and conduct around launch. Product information, intended uses, supply steps and regulatory representations may all be relevant. In some cases, the issue is not only whether your business directly infringes, but whether it could be said to authorise or participate in infringing conduct by others.

Finally, businesses should remember the procedural point. Interlocutory applications can move quickly, often on affidavit and expert evidence without cross-examination. If a dispute is brewing, waiting until the last minute can leave very little room to respond properly.

The judgment is dated 5 December 2025 and concerns an interlocutory injunction application in the Federal Court of Australia. The patent in suit had a priority date of 19 December 2007 and, according to the judgment, expires on 17 December 2028. Juno became the ARTG sponsor for the relevant products on 28 February 2025.

This page reflects an interim decision only. It should not be read as a final statement that the patent is valid or that infringement has been conclusively established. It should also be read with care because the publicly available material is truncated and the reasons were subject to confidentiality handling. Readers who need the exact scope of the restraint or the full reasoning should check the final published judgment and orders.